Recipharm AB Offer Closed (6650I)
April 03 2020 - 2:00AM
UK Regulatory
TIDM0QSD TIDMTTM
RNS Number : 6650I
Recipharm AB
03 April 2020
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT
JURISDICTION
FOR IMMEDIATE RELEASE
3 April 2020
Recommended Cash Offer
for
Consort Medical plc
By
Recipharm Holdings Limited
a directly wholly-owned subsidiary of Recipharm AB
Offer Closed
On 4 February 2020, the boards of Recipharm Holdings Limited
("Recipharm") and Consort Medical plc ("Consort") announced that
the recommended cash offer (the "Offer") to acquire the entire
issued and to be issued share capital of Consort had been declared
unconditional in all respects. The full terms of, and conditions
to, the Offer and the procedures for acceptance were set out in the
offer document dated 6 December 2019 (the "Offer Document"). The
definitions set out in the Offer Document dated 6 December 2019
have the same meanings in this announcement.
On 17 February 2020, Recipharm announced that the Offer would
remain open for acceptances until 1.00 p.m. (London time) on 2
April 2020.
On 2 April 2020, Recipharm completed the exercise of its rights
pursuant to the provisions of Chapter 3 of Part 28 of the Companies
Act 2006 to acquire compulsorily the remaining Consort Shares in
respect of which the Offer had not been accepted on the same terms
as the Offer.
Closing of the Offer
Recipharm announces that it has acquired the entire issued share
capital of Consort.
The Offer is therefore closed to further acceptances with effect
from 1.00 p.m. (London time) on 2 April 2020.
Further information
This announcement is for information purposes only and is not
intended to and does not constitute or form part of, any offer,
invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of any
securities, or the solicitation of any vote or approval in any
jurisdiction, pursuant to the Offer or otherwise nor shall there be
any sale, issuance or transfer of securities of Consort in any
jurisdiction in contravention of applicable law.
Overseas Shareholders
This announcement has been prepared in accordance with English
law, the Takeover Code, the Market Abuse Regulation and the
Disclosure Guidance and Transparency Rules and information
disclosed may not be the same as that which would have been
prepared in accordance with the laws of jurisdictions outside
England. The statements contained in this announcement are made as
at the date of this announcement, unless some other time is
specified in relation to them, and there shall be no implication
that there has been no change in the facts set forth in this
announcement since such date.
The Offer is subject to the applicable rules and regulations of
the FCA, the London Stock Exchange and the Takeover Code.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
OUPFFFVLSEIFIII
(END) Dow Jones Newswires
April 03, 2020 02:00 ET (06:00 GMT)
Recipharm AB (LSE:0QSD)
Historical Stock Chart
From Sep 2024 to Oct 2024
Recipharm AB (LSE:0QSD)
Historical Stock Chart
From Oct 2023 to Oct 2024